Kristen Oelschlager Sells 12,384 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 12,384 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $34.42, for a total transaction of $426,257.28. Following the sale, the chief operating officer owned 72,649 shares of the company’s stock, valued at approximately $2,500,578.58. The trade was a 14.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Castle Biosciences Stock Up 0.5%

CSTL opened at $34.26 on Friday. The company has a market cap of $1.05 billion, a P/E ratio of -51.91 and a beta of 0.98. The business’s 50-day moving average price is $26.99 and its 200-day moving average price is $25.42. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12 month low of $17.72 and a 12 month high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The company had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. On average, equities analysts expect that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Robert W. Baird set a $36.00 price objective on Castle Biosciences in a research note on Friday, July 31st. Roth Capital began coverage on shares of Castle Biosciences in a research note on Wednesday, June 24th. They issued a “buy” rating and a $40.00 target price on the stock. KeyCorp set a $35.00 price target on shares of Castle Biosciences in a report on Friday, May 29th. BTIG Research increased their price target on shares of Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Institutional Investors Weigh In On Castle Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System grew its position in shares of Castle Biosciences by 3,176.9% in the 2nd quarter. California State Teachers Retirement System now owns 901,578 shares of the company’s stock worth $21,503,000 after buying an additional 874,065 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Castle Biosciences during the second quarter valued at approximately $3,395,000. Jefferies Financial Group Inc. bought a new position in shares of Castle Biosciences during the second quarter valued at approximately $15,440,000. Bank of America Corp DE purchased a new stake in Castle Biosciences in the second quarter worth $2,355,000. Finally, Man Group plc bought a new stake in Castle Biosciences in the second quarter valued at $2,594,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.